ETON News & Events

Eton Pharmaceuticals announced it has entered into a supply and distribution agreement for the United States commercialization rights to Impavido from an affiliate of Knight Therapeutics. Impavido is an orphan drug indicated for the treatment of visceral, cutaneous, and mucosal leishmaniasis caused by specific Leishmania species in adults and adolescents over the age of 12 and weighing more than 30 kilograms.

Eton Pharmaceuticals announced the relaunch of Hemangeol. Hemangeol is the only FDA-approved treatment for infantile hemangioma, a pediatric rare disease that can be time-sensitive. Hemangeol is now available exclusively through Anovo Specialty Pharmacy to streamline access and therapy initiation.

Eton Pharmaceuticals announced the first patient has been dosed in a pilot clinical study assessing the efficacy of ET-700, the company's proprietary, patent-pending formulation of extended-release zinc acetate under development for the treatment of Wilson disease. Topline study results are expected in the second half of 2026, and if positive, would lead to a pivotal clinical study in early 2027."ET-700 has the potential to deliver a major advancement for patients with Wilson disease, and we're excited to initiate this clinical study. Based on feedback from the patient community and treating physicians, there remains a meaningful need for more convenient, simpler dosing approaches for this lifelong chronic therapy, which ET-700 is designed to explore. If approved, we believe ET-700 could exceed $100 million of peak annual sales in the United States," said Sean Brynjelsen, CEO of Eton Pharmaceuticals.